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Abstract
Background: Acu-point specificity is a key issue in acupuncture. To date there has not been any satisfactory trial
which can ratify the specific effect of acupuncture. This trial will evaluate the specific effect of BL33 for mild and
moderate benign prostatic hyperplasia (BPH) on the basis of its effectiveness. The non-specific effect will be
excluded and the therapeutic effect will be evaluated.
Method: This is a double-blinded randomized controlled trial. 100 Patients will be randomly allocated into the
treatment group (n = 50) and the control group (n = 50). The treatment group receives needling at BL33 and the
control group receives needling at non-point. The needling depth, angle, direction, achievement of De Qi and
parameters of electroacupuncture are exactly the same in both groups. The primary outcome measure is reduction
of international prostate symptom score (IPSS) at the 6
th week and the secondary outcome measures are reduction
of bladder residual urine, increase in maximum urinary flow rate at the 6
th week and reduction of IPSS at the 18
th
week.
Discussion: This trial will assess the specific therapeutic effect of electroacupuncture at BL33 for mild and
moderate BPH.
Trial registration: Protocol Registration System of Clinical Trials.gov NCT01218243
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1. Background
For thousands of years, points of the fourteen meridians
have always maintained their specific locations, and
therapeutic indications. Point specificity is the central
part of acupuncture and plays an important role in clini-
cal practice. It has been proved by Cochrane reviews
that acupuncture is effective for migraine prophylaxis,
tension headache and chemotherapy-induced nausea or
vomiting [1-3]. But there still remains a level of uncer-
tainty about the specificity of some acupuncture ponits
[4]. The difficulty in resolving this problem is due to the
fact that acupuncture outcome is influenced by complex
interplay of insertion depth, angle, and achievement of
De Qi. Recently published trials in Germany show that
acupuncture was no more effective than sham acupunc-
ture for migraine, headache and knee osteoarthritis
[5-8]. One could attribute it to adenosine’sr o l ei nt h e
mechanistic actions of acupuncture. According to the
latest research [9], ATP release from keratinocytes in
response to insertion and manual rotation of acupunc-
ture needles results in an accumulation of adenosine
that transiently reduces pain. If relief of pain is purely a
response to mechanical stimulation, then it does not
matter much which acupuncture point is being used.
Hence, it is not appropriate to study point specificity
with pain syndromes.
Study on point specificity began in China in the 1980s
a n di th a sb e e nf o u n dt h a tp o i n t so ft h ef o u r t e e n
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zang-fu organs [10-12], such as St36’s specific effect for
visceralgia and SI19’s specific relationship with the ear.
According to the results of those studies and our clinical
practice, we took a trial showing that electroacupunc-
ture at BL33 can reduce IPSS by 6.52 ± 0.41 (n = 47)
[13] and 6.68 ± 2.84 (n = 87) [14]and improve the
symptoms of difficult urination in mild or moderate
patients with BPH. Its effect is better than that of tera-
zosin. Also in our pilot trial (n = 40), 40 patients were
randomized into the treatment group (BL33) and the
control group (non-point acupuncture site located
beside BL33). The result shows that electroacupuncture
at BL33 has better effect in reducing IPSS and bladder
residual urine and increasing maximum urinary flow
rate than electroacupuncture at non-point. There is sig-
nificant improvement with urinary frequency and noc-
turia in the treatment group as compared with the
control group [15].
This trial is a large-scale prospective randomized trial
after the pilot study. Patients and assessors are blinded
with regard to acupuncture treatment given. It will com-
pare needling at BL33 with needling at non- point. The
same manipulating methods (needling depth, angle,
direction and achievement of De Qi,.) could cause the
same needle sensation between the two groups. As all
points used in the trial are on the back area where
patients are unable to see, thus blinding for the patients
could be applied successfully. The study is registered
with an identifier (NCT01218243) by Clinical Trials.gov
in USA.
2. Methods and Design
2.1 Design
This study is a prospective randomized controlled trial
and will be completed in Acupuncture Department of
Guang’anmen Hospital affiliated to China Academy of
Chinese Medical Sciences from Sep. 2010 to July 2012.
Randomization is performed by Drug Clinical Trial
Office affiliated to Guang’anmen Hospital. Computer-
made opaque sealed envelopes are numbered consecu-
tively. All of the envelopes are preserved by an investiga-
tor (who is uninvolved in acupuncture operation and
data analysis). After the baseline assessment has been
carried out and the informed consent has been obtained,
an envelope is opened by the investigator according to
patient’s sequence entering the trial and the allocated
treatment regimen is offered to the clinician. Two copies
of the envelopes will be kept to guard against research-
ers trying to change the randomization.
Participants are recruited from PBH clinic in the hos-
pital by the use of local newspaper advertisements and
posted notices at clinic site. Patients on mediciation for
urinary symptoms are requested to stop medication one
week before baseline assessment. Before randomization,
patients will complete 1-week baseline assessment which
includes IPSS, bladder residual urine and maximum
urinary flow rate and they will be divided into three
groups according to their IPSS score, i.e. the mild group
(0-7), moderate group (8-19) and the severe group (20-
35). Patients belonging to the severe group will be
excluded.
Enrolled patients will be randomized into the treat-
ment group or the control group. The diagnosis and
assessment will be made by an independent urologist
who is uninvolved in the treatment process. Acupunc-
ture will be given 5 sessions/week in the first two weeks
and 3 sessions/week in the third and the fourth weeks, a
total of 16 sessions.
The trial protocol is in accordance with the principles
of the Declaration of Helsinki and has been approved by
the review board and ethics committee of the hospital.
Participants will be request e dt os i g na ni n f o r m e dc o n -
sent before any treatment is given. All patients have
right to decide whether they would sign up or not and
they can withdraw from the trial at any time (Figure 1).
Patients
According to our 40-case pilot trial and study of Christo-
pher R. Chapple and Hong-Jeng Yu [16,17], to detect a
reduction in IPSS of 7 with a two-sided 5% significance
level and a power of 90%, 50 patients will be needed for
treatment group and control group respectively (1:1 allo-
cation) allowing for a 20% dropout rate [18].
n =n 1=n 2=( U α +U β)2 ×

1+1 / k

s2/δ2
Inclusion criteria
According to the diagnosis recommended by the fifth
international BPH Consulting Committee, patients who
meet the following criteria will be recruited: 1) 50-70
years old; 2) mild to moderate BPH evaluated by I-PSS;
3) patients having urinary dysfunction more than 3
months; 4) patients with stable life signs; 5) no use of
a1 receptor blocker, 5a- r e d u c t a s ei n h i b i t o ro rt r a d i -
tional Chinese medicine for over 1 week; 6) volunteer to
join this research and give informed consent prior to
receiving treatment.
Exclusion criteria
Patients with any of the following conditions will be
excluded: 1) urinary dysfunction caused by gonorrhea or
urinary tract infection; 2) oliguria and anuria caused by
urinary calculi, prostate cancer, bladder tumor and
acute/chronic renal failure; 3) urinary dysfunction
caused by neurogenic bladder, bladder neck fibrotic and
urethral stricture; 4) failure of invasive therapy for pro-
static obstruction; 5) injured local organs, muscle and
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urinary obstruction and hydrocele combined with
damaged renal function due to BPH diagnosed by B-
ultrasound; 7) Patients unable to commit to treatment
because of commuting problems to the hospital.
Interventions
In addition to records in ancient books [19], we also
choose this acupuncture point according to our
published study [13,14] and a consensus with acupunc-
ture experts in Beijing. Huatuo Brand needle (0.3*100
mm, Suzhou Medical Appliance Factory CL) and
G6805-2 electric stimulator (Shanghai Huayi Medical
Instrument Co.Ltd) will be used in the trial.
Treatment group
Needle at bilateral BL33 with a 45°angle. A feeling of
soreness and distension will be felt when needling into
the 3rd posterior sacral foramina (S3) and finally with
Patients entered 
Informed consent 
Control group˄n=50˅ 
16 sessions for 4 weeks 
Treatment group(n=50˅  
16 sessions for 4 weeks 
6
th week: IPSS, bladder residual urine, max urinary flow rate 
18
th week: IPSS 
Data collection and analysis 
Baseline assessments: IPSS, bladder 
residual urine, max urinary flow rate 
Randomization 
(n=100) 
Patients excluded 
Figure 1 Flow chart of the trial.
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mm without lifting, thrusting or rotating. Put on the
electric stimulator with a disperse-dense wave, 20Hz.
The current intensity is increased to the patients’ maxi-
mum tolerance and then slightly reduced to a bearable
level.
Control group
T a k et h es i t e2cun lateral BL33 as the non-point (Fig-
ure 2) for the control group. Manipulation methods and
electric stimulator parameters are the same with those
of the treatment group. The pilot study shows that
patients in the control group have the same feeling with
those of the treatment group.
There are 16 sessions for all patients (5 sessions in the
1
st and 2
nd weeks, 3 sessions in the 3
rd and 4
th weeks)
and each session last 30 minutes. Acupuncture for the
two groups will be operated by the same acupuncturist
with more than ten years of experience. This acupunc-
turist is blinded to the outcome assessment at baseline,
the 6
th week and the 18
th week.
Outcome measures
The primary outcome measure is reduction of interna-
tional prostate symptom score (IPSS) at the 6th week
compared with baseline. The secondary outcome mea-
sures are reduction of bladder residual urine, increase in
maximum urinary flow rate at the 6th week and reduc-
tion of IPSS at the 18
th week.
Safety evaluation is based on adverse events which
include hematoma, fainting, severe pain, and local infec-
tion. Any adverse event and the time and measures to
take will be recorded in detail during treatment.
Statistical analysis
The statistical analysis will be performed by a statistician
blinded to allocation in Clinical Evaluation Center of
China Academy of Chinese Medical Sciences. Statistical
analyses will be performed using the SPSS statistical
package program (ver.16.0) and the level of significance
will be established at a < 0.05. The data analysis of
baseline characteristics is based on the intention-to-treat
(ITT) population (data of all participants who are rando-
mized will be analyzed). The data analysis of the pri-
mary and secondary outcomes is mainly based on the
ITT population. In addition, the data analysis of the pri-
mary outcome is also based on per-protocol (PP) popu-
lation as a supportive analysis.
For primary and secondary outcome measures, analy-
sis of covariance will be used to investigate whether
BL33 acupuncture is more effective than non-acupoint
acupuncture.
Quality control
Before the trial, all staff involved will be trained in
patients selection and exclusion, filling up of the case
report and acupuncture method. During the trial, super-
visors will check on case reports, and acupuncture
operation twice a month. Drop-outs, withdrawals (and
the reasons), the compliance of all patients will be
recorded in detail throughout the treatment and follow-
up period.
Discussion
The point specificity has been a controversial research
topic for a long time [20] and it has become a point of
Non-point  BL33 
Figure 2 BL33 and non-point used in the trial.
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Germany as previously mentioned. But from the view-
point of Nanna Goldman [9], anti-nociceptive effect of
acupuncture is a general reaction to the mechanical sti-
mulation leading to the belief that pain syndrome
should not be used in point specificity study at the pre-
sent time.
The reasons we choose BPH for point specificity
include: 1) studies show that acupoints have specific
effect in regulating function of zang-fu organs [10-12]
and BPH is appropriate for this kind of study; 2) our
previous study shows that electroacupuncture has effect
in improving the symptoms of BPH and the effect is
better than that of non-acupoint acupuncture; 3) a sin-
gle point acupuncture is most suited for point specificity
study.
In this trial, points used here are on the back area
where patients unable to see and patients of the two
groups have the same feeling because the manipulation
methods are all the same. So patients are blinded as to
which treatment they will receive. As the manipulation
methods of the two groups are the same, the different
effects between the two groups will be completely pro-
duced by point location, which will give a good explana-
tion of point specificity. And also the placebo effect could
be excluded and the specific effect of electroacupuncture
at BL33 could be investigated. As electroacupuncture is
also used in the control group with the same parameter
and same insertion depth, part of treatment effect could
be achieved. So part of specific effect of the treatment
group will be excluded inevitably (Figure 3).
This study will follow rigorous methodological
requirements. The staffs in charge of assessment and
statistician are all blinded to the patients’ allocation.
Acupuncture operation(performed by an experienced
acupuncturist)and filling of case report (by a postgradu-
ate) form will be done under strict supervision. Phone
calls and e-mails will be used to inform the patients for
follow-up assessment which will be done at their homes
or in the clinic. Any medicine taken and other treatment
conducted during this time will be recorded in detail.
Conclusion
The aim of this study is to investigate whether BL33
acupuncture is more effectivet h a nn o n - a c u p o i n ta c u -
puncture, i.e. point specificity of BL33 for BPH.
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